Prostate Cancer

Androgen deprivation therapy in men with prostate cancer was not associated with changes in clinical pain (BPI), pressure pain thresholds, cold pain tolerance, mechanical pain temporal summation, or c

Effect: null; 0.31; CI: 95% CI = -0.55 to 1.17

Androgen deprivation therapy in men with prostate cancer was not associated with changes in clinical pain (BPI), pressure pain thresholds, cold pain tolerance, mechanical pain temporal summation, or c

Effect: null; 0.31; CI: 95% CI = -0.55 to 1.17

Androgen deprivation therapy in men with prostate cancer was not associated with changes in clinical pain (BPI), pressure pain thresholds, cold pain tolerance, mechanical pain temporal summation, or c

Effect: null; 0.31; CI: 95% CI = -0.55 to 1.17

Androgen deprivation therapy in men with prostate cancer was not associated with changes in clinical pain (BPI), pressure pain thresholds, cold pain tolerance, mechanical pain temporal summation, or c

Effect: null; 0.31; CI: 95% CI = -0.55 to 1.17

Androgen deprivation therapy in men with prostate cancer was not associated with changes in clinical pain (BPI), pressure pain thresholds, cold pain tolerance, mechanical pain temporal summation, or c

Effect: null; 0.31; CI: 95% CI = -0.55 to 1.17

Androgen deprivation therapy in men with prostate cancer was not associated with changes in clinical pain (BPI), pressure pain thresholds, cold pain tolerance, mechanical pain temporal summation, or c

Effect: null; 0.31; CI: 95% CI = -0.55 to 1.17

Androgen deprivation therapy in men with prostate cancer was not associated with changes in clinical pain (BPI), pressure pain thresholds, cold pain tolerance, mechanical pain temporal summation, or c

Effect: null; 0.31; CI: 95% CI = -0.55 to 1.17

Androgen deprivation therapy in men with prostate cancer was not associated with changes in clinical pain (BPI), pressure pain thresholds, cold pain tolerance, mechanical pain temporal summation, or c

Effect: null; 0.31; CI: 95% CI = -0.55 to 1.17

Androgen deprivation therapy in men with prostate cancer was not associated with changes in clinical pain (BPI), pressure pain thresholds, cold pain tolerance, mechanical pain temporal summation, or c

Effect: null; 0.31; CI: 95% CI = -0.55 to 1.17

Androgen deprivation therapy in men with prostate cancer was not associated with changes in clinical pain (BPI), pressure pain thresholds, cold pain tolerance, mechanical pain temporal summation, or c

Effect: null; 0.31; CI: 95% CI = -0.55 to 1.17

Androgen deprivation therapy in men with prostate cancer was not associated with changes in clinical pain (BPI), pressure pain thresholds, cold pain tolerance, mechanical pain temporal summation, or c

Effect: null; 0.31; CI: 95% CI = -0.55 to 1.17

Androgen deprivation therapy in men with prostate cancer was not associated with changes in clinical pain (BPI), pressure pain thresholds, cold pain tolerance, mechanical pain temporal summation, or c

Effect: null; 0.31; CI: 95% CI = -0.55 to 1.17

Androgen deprivation therapy in men with prostate cancer was not associated with changes in clinical pain (BPI), pressure pain thresholds, cold pain tolerance, mechanical pain temporal summation, or c

Effect: null; 0.31; CI: 95% CI = -0.55 to 1.17

Androgen deprivation therapy in men with prostate cancer was not associated with changes in clinical pain (BPI), pressure pain thresholds, cold pain tolerance, mechanical pain temporal summation, or c

Effect: null; 0.31; CI: 95% CI = -0.55 to 1.17

Androgen deprivation therapy in men with prostate cancer was not associated with changes in clinical pain (BPI), pressure pain thresholds, cold pain tolerance, mechanical pain temporal summation, or c

Effect: null; 0.31; CI: 95% CI = -0.55 to 1.17

Androgen deprivation therapy in men with prostate cancer was not associated with changes in clinical pain (BPI), pressure pain thresholds, cold pain tolerance, mechanical pain temporal summation, or c

Effect: null; 0.31; CI: 95% CI = -0.55 to 1.17

Androgen deprivation therapy in men with prostate cancer was not associated with changes in clinical pain (BPI), pressure pain thresholds, cold pain tolerance, mechanical pain temporal summation, or c

Effect: null; 0.31; CI: 95% CI = -0.55 to 1.17

Androgen deprivation therapy in men with prostate cancer was not associated with changes in clinical pain (BPI), pressure pain thresholds, cold pain tolerance, mechanical pain temporal summation, or c

Effect: null; 0.31; CI: 95% CI = -0.55 to 1.17

Androgen deprivation therapy in men with prostate cancer was not associated with changes in clinical pain (BPI), pressure pain thresholds, cold pain tolerance, mechanical pain temporal summation, or c

Effect: null; 0.31; CI: 95% CI = -0.55 to 1.17

Androgen deprivation therapy in men with prostate cancer was not associated with changes in clinical pain (BPI), pressure pain thresholds, cold pain tolerance, mechanical pain temporal summation, or c

Effect: null; 0.31; CI: 95% CI = -0.55 to 1.17

Androgen deprivation therapy in men with prostate cancer was not associated with changes in clinical pain (BPI), pressure pain thresholds, cold pain tolerance, mechanical pain temporal summation, or c

Effect: null; 0.31; CI: 95% CI = -0.55 to 1.17

Androgen deprivation therapy in men with prostate cancer was not associated with changes in clinical pain (BPI), pressure pain thresholds, cold pain tolerance, mechanical pain temporal summation, or c

Effect: null; 0.31; CI: 95% CI = -0.55 to 1.17

Androgen deprivation therapy in men with prostate cancer was not associated with changes in clinical pain (BPI), pressure pain thresholds, cold pain tolerance, mechanical pain temporal summation, or c

Effect: null; 0.31; CI: 95% CI = -0.55 to 1.17

Androgen deprivation therapy in men with prostate cancer was not associated with changes in clinical pain (BPI), pressure pain thresholds, cold pain tolerance, mechanical pain temporal summation, or c

Effect: null; 0.31; CI: 95% CI = -0.55 to 1.17

Androgen deprivation therapy in men with prostate cancer was not associated with changes in clinical pain (BPI), pressure pain thresholds, cold pain tolerance, mechanical pain temporal summation, or c

Effect: null; 0.31; CI: 95% CI = -0.55 to 1.17

Androgen deprivation therapy in men with prostate cancer was not associated with changes in clinical pain (BPI), pressure pain thresholds, cold pain tolerance, mechanical pain temporal summation, or c

Effect: null; 0.31; CI: 95% CI = -0.55 to 1.17

Androgen deprivation therapy in men with prostate cancer was not associated with changes in clinical pain (BPI), pressure pain thresholds, cold pain tolerance, mechanical pain temporal summation, or c

Effect: null; 0.31; CI: 95% CI = -0.55 to 1.17

Men undergoing ADT experienced statistically significant worsening in physical role limitation quality of life compared to eugonadal controls, while other QOL domains (emotional well-being, emotional

Effect: adverse; -18.28; CI: 95%CI= -30.18 to -6.37

Men undergoing ADT experienced statistically significant worsening in physical role limitation quality of life compared to eugonadal controls, while other QOL domains (emotional well-being, emotional

Effect: adverse; -18.28; CI: 95%CI= -30.18 to -6.37

Men undergoing ADT experienced statistically significant worsening in physical role limitation quality of life compared to eugonadal controls, while other QOL domains (emotional well-being, emotional

Effect: adverse; -18.28; CI: 95%CI= -30.18 to -6.37

Men undergoing ADT experienced statistically significant worsening in physical role limitation quality of life compared to eugonadal controls, while other QOL domains (emotional well-being, emotional

Effect: adverse; -18.28; CI: 95%CI= -30.18 to -6.37

Men undergoing ADT experienced statistically significant worsening in physical role limitation quality of life compared to eugonadal controls, while other QOL domains (emotional well-being, emotional

Effect: adverse; -18.28; CI: 95%CI= -30.18 to -6.37

Men undergoing ADT experienced statistically significant worsening in physical role limitation quality of life compared to eugonadal controls, while other QOL domains (emotional well-being, emotional

Effect: adverse; -18.28; CI: 95%CI= -30.18 to -6.37

Men undergoing ADT experienced statistically significant worsening in physical role limitation quality of life compared to eugonadal controls, while other QOL domains (emotional well-being, emotional

Effect: adverse; -18.28; CI: 95%CI= -30.18 to -6.37

Men undergoing ADT experienced statistically significant worsening in physical role limitation quality of life compared to eugonadal controls, while other QOL domains (emotional well-being, emotional

Effect: adverse; -18.28; CI: 95%CI= -30.18 to -6.37

Men undergoing ADT experienced statistically significant worsening in physical role limitation quality of life compared to eugonadal controls, while other QOL domains (emotional well-being, emotional

Effect: adverse; -18.28; CI: 95%CI= -30.18 to -6.37

Men undergoing ADT experienced statistically significant worsening in physical role limitation quality of life compared to eugonadal controls, while other QOL domains (emotional well-being, emotional

Effect: adverse; -18.28; CI: 95%CI= -30.18 to -6.37

Men undergoing ADT experienced statistically significant worsening in physical role limitation quality of life compared to eugonadal controls, while other QOL domains (emotional well-being, emotional

Effect: adverse; -18.28; CI: 95%CI= -30.18 to -6.37

Men undergoing ADT experienced statistically significant worsening in physical role limitation quality of life compared to eugonadal controls, while other QOL domains (emotional well-being, emotional

Effect: adverse; -18.28; CI: 95%CI= -30.18 to -6.37

Men undergoing ADT experienced statistically significant worsening in physical role limitation quality of life compared to eugonadal controls, while other QOL domains (emotional well-being, emotional

Effect: adverse; -18.28; CI: 95%CI= -30.18 to -6.37

Men undergoing ADT experienced statistically significant worsening in physical role limitation quality of life compared to eugonadal controls, while other QOL domains (emotional well-being, emotional

Effect: adverse; -18.28; CI: 95%CI= -30.18 to -6.37

Men undergoing ADT experienced statistically significant worsening in physical role limitation quality of life compared to eugonadal controls, while other QOL domains (emotional well-being, emotional

Effect: adverse; -18.28; CI: 95%CI= -30.18 to -6.37

Men undergoing ADT experienced statistically significant worsening in physical role limitation quality of life compared to eugonadal controls, while other QOL domains (emotional well-being, emotional

Effect: adverse; -18.28; CI: 95%CI= -30.18 to -6.37

Men undergoing ADT experienced statistically significant worsening in physical role limitation quality of life compared to eugonadal controls, while other QOL domains (emotional well-being, emotional

Effect: adverse; -18.28; CI: 95%CI= -30.18 to -6.37

Men undergoing ADT experienced statistically significant worsening in physical role limitation quality of life compared to eugonadal controls, while other QOL domains (emotional well-being, emotional

Effect: adverse; -18.28; CI: 95%CI= -30.18 to -6.37

Men undergoing ADT experienced statistically significant worsening in physical role limitation quality of life compared to eugonadal controls, while other QOL domains (emotional well-being, emotional

Effect: adverse; -18.28; CI: 95%CI= -30.18 to -6.37

Men undergoing ADT experienced statistically significant worsening in physical role limitation quality of life compared to eugonadal controls, while other QOL domains (emotional well-being, emotional

Effect: adverse; -18.28; CI: 95%CI= -30.18 to -6.37

Men undergoing ADT experienced statistically significant worsening in physical role limitation quality of life compared to eugonadal controls, while other QOL domains (emotional well-being, emotional

Effect: adverse; -18.28; CI: 95%CI= -30.18 to -6.37

Men undergoing ADT experienced statistically significant worsening in physical role limitation quality of life compared to eugonadal controls, while other QOL domains (emotional well-being, emotional

Effect: adverse; -18.28; CI: 95%CI= -30.18 to -6.37

Men undergoing ADT experienced statistically significant worsening in physical role limitation quality of life compared to eugonadal controls, while other QOL domains (emotional well-being, emotional

Effect: adverse; -18.28; CI: 95%CI= -30.18 to -6.37